Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study

• Status: Withdrawn
• Trial end date: 2018-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Database analysis:

• To describe how Orencia is prescribed in France in Rheumatoid Arthritis (RA)

• To describe joint population of Orencia

• To assess the impact of the treatment on health status of the treated population as assessed by morbid-mortality criteria

• To describe therapeutic strategies and use of health services

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Abatacept

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

• Adult outpatients, male or female aged ≥ 18 years old

• Diagnosed with a rheumatoid arthritis according to ACR criteria

• Treated with Orencia according to usual practice conditions from June 1st 2007

• Agreeing to participate

Exclusion Criteria:

• Patients treated by Orencia in the context of clinical trials